SK684990A3 - Drug composed of a first and second active substance - Google Patents

Drug composed of a first and second active substance Download PDF

Info

Publication number
SK684990A3
SK684990A3 SK6849-90A SK684990A SK684990A3 SK 684990 A3 SK684990 A3 SK 684990A3 SK 684990 A SK684990 A SK 684990A SK 684990 A3 SK684990 A3 SK 684990A3
Authority
SK
Slovakia
Prior art keywords
histone
fragment
active
medicament according
active substance
Prior art date
Application number
SK6849-90A
Other languages
English (en)
Slovak (sk)
Other versions
SK279960B6 (sk
Inventor
Michael Zeppezauer
Hans-Peter Leinenbach
Original Assignee
Symbiotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symbiotec Gmbh filed Critical Symbiotec Gmbh
Publication of SK684990A3 publication Critical patent/SK684990A3/sk
Publication of SK279960B6 publication Critical patent/SK279960B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK6849-90A 1990-01-04 1990-12-28 Liečivo zložené z prvej a druhej účinnej látky SK279960B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4000154A DE4000154A1 (de) 1990-01-04 1990-01-04 Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen

Publications (2)

Publication Number Publication Date
SK684990A3 true SK684990A3 (en) 1999-06-11
SK279960B6 SK279960B6 (sk) 1999-06-11

Family

ID=6397630

Family Applications (1)

Application Number Title Priority Date Filing Date
SK6849-90A SK279960B6 (sk) 1990-01-04 1990-12-28 Liečivo zložené z prvej a druhej účinnej látky

Country Status (9)

Country Link
US (1) US5578571A (fr)
EP (1) EP0438756B1 (fr)
JP (1) JPH0813756B2 (fr)
AT (1) ATE104553T1 (fr)
CA (1) CA2033249C (fr)
CZ (1) CZ283924B6 (fr)
DE (2) DE4000154A1 (fr)
SK (1) SK279960B6 (fr)
UA (1) UA27704C2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780432A (en) * 1990-12-28 1998-07-14 Allegheny University Of The Health Sciences Therapeutic method for treatment of carcinoma or autoimmune diseases
WO1996040170A2 (fr) * 1995-06-07 1996-12-19 Procept, Inc. Composes contenant des metaux et leur utilisation pour inhiber la reponse immunitaire
DE19715149A1 (de) * 1997-04-11 1998-10-15 Symbiotec Gmbh Krebstherapeutikum und Diagnose zur Charakterisierung von Krebszellen mit individueller Eigenschaft
US20030017987A1 (en) 1997-04-11 2003-01-23 Michael Zeppezauer Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties
KR100261114B1 (ko) * 1998-01-24 2000-07-01 박종헌 히스톤을 함유하는 류마티스 관절염 치료제 조성물
US6884423B1 (en) * 1998-08-13 2005-04-26 Symbiotec Gmbh Antimicrobial histone H1 compositions, kits, and methods of use thereof
CN1296974A (zh) * 1999-11-23 2001-05-30 上海博容基因开发有限公司 一种新的多肽——人组蛋白h2a.21和编码这种多肽的多核苷酸
US20040219140A1 (en) * 2001-02-22 2004-11-04 Reiner Class Compositions and methods for preventing platelet aggregation
DE102005022319A1 (de) 2005-05-10 2006-11-23 Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh Verwendung von Histonen zu therapeutischen Zwecken
US8778875B2 (en) * 2005-08-05 2014-07-15 Symbiotec Gesellschaft zur Forshung und Entwickling auf dem Gebiet der Biotechnologie, mbH Use of an active biological substance in abnormal cellular and viral membrane physiologies
EP2123266B1 (fr) * 2006-12-06 2014-01-15 Kaneka Corporation Agent thérapeutique contre le cancer et agent anti-carcinogène
US20140135337A1 (en) 2011-05-16 2014-05-15 Genzyme Corporation Induction of immune tolerance by using methotrexate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
JPS63139134A (ja) * 1986-12-02 1988-06-10 Kyowa Hakko Kogyo Co Ltd Ｔ細胞活性化剤
DE3737274A1 (de) * 1987-11-03 1989-06-01 Rusch Volker Verwendung von reinem h2a- und/oder h2b-histon als wirksubstanz zur herstellung von arzneimitteln
ES2045092T3 (es) * 1987-11-11 1994-01-16 Akzo Nv Un procedimiento de manufactura de un producto farmaceutico para tratamiento de cancer.

Also Published As

Publication number Publication date
CZ684990A3 (cs) 1998-04-15
US5578571A (en) 1996-11-26
CA2033249A1 (fr) 1991-07-05
ATE104553T1 (de) 1994-05-15
CZ283924B6 (cs) 1998-07-15
JPH0813756B2 (ja) 1996-02-14
DE59005456D1 (de) 1994-05-26
CA2033249C (fr) 1997-01-21
JPH04305535A (ja) 1992-10-28
DE4000154A1 (de) 1991-07-11
EP0438756B1 (fr) 1994-04-20
EP0438756A1 (fr) 1991-07-31
UA27704C2 (uk) 2000-10-16
SK279960B6 (sk) 1999-06-11

Similar Documents

Publication Publication Date Title
US5428011A (en) Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
Brines et al. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise
SK684990A3 (en) Drug composed of a first and second active substance
US5736519A (en) Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5595973A (en) Protection of hemopoietic cells during chemotherapy or radiotherapy
CA1322713C (fr) Compositions et methodes pour moduler l'effet de tnf et il-1
IE901297L (en) Use of cytokines for treating preneoplastic lesions
KR20080099234A (ko) 콤브레타스타틴 및 항암제를 포함하는 조합물
JPS62501705A (ja) 腫瘍性疾患の治療に用いるプログルミド含有医薬組成物
US5843422A (en) Method and compositions for treating injury
KR20030008368A (ko) 세포고사 유도성 화학 요법 제제의 투여에 의한 암 치료방법 및 이를 위한 조성물
JP2848922B2 (ja) 胸膜の原発癌を治療する意図の薬剤組成物を製造するためのヒトインターロイキン２の活性を有するポリペプチドの使用
WO1996001121A1 (fr) Therapie anticancereuse utilisant la lymphotoxine
EP0295559B1 (fr) Composition pharmaceutique pour le traitement des tumeurs
CZ300496B6 (cs) Prostredky, zpusob jejich prípravy a použití
Parker et al. Inhibitors of haemopoiesis and their potential clinical relevance
AU758856C (en) Compositions containing muscle-derived active agents
EP0835662A2 (fr) Médicament pour le traitement du cancer
US6410515B1 (en) Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US20030050233A1 (en) Peptide combination for the treatment of cancer
US5747454A (en) Chromogranin peptides
CA2284105A1 (fr) Peptides neurotrophiques de synthese derives de la saposine c
US5593965A (en) Anti-tumor effects of GnRH-III
JPS63501724A (ja) 腫瘍壊死因子及び抗生物質及び腫瘍処理方法の組合せ
AU638839C (en) Method and compositions for treating injury